Market-Moving News for September 16th
Market-Moving News for September 16th
NCNA: 282% | NuCana Presented Final Data From Phase 2 Nutide:701 Study At ESMO Congress On NUC-7738 In Combination With Pembrolizumab For Patients With Metastatic Melanoma Who Were Refractory To Or Had Relapsed On Prior PD-1 Inhibitor Therapy
NCNA: 282% | nucana在ESMO大會上展示了2期Nutide:701研究中終稿數據，該研究針對PD-1抑制劑治療無效或復發的轉移性黑色素瘤患者，NUC-7738與pembrolizumab聯合應用。
ZNTL: 49% | Zentalis Pharmaceuticals shares are trading higher after the company announced that the FDA lifted the partial clinical hold on studies of azenosertib and remains on track to meet all previously disclosed data guidance for the remainder of 2024.
ZNTL: 49% | zentalis pharmaceuticals股價上漲，因該公司宣佈FDA解除對azenosertib研究的部分臨床暫停，仍然按照之前公佈的數據指導計劃完成2024年剩餘部分的研究。
ITOS: -16% | iTeos Therapeutics shares are trading lower. The company announced follow-up interim data from GALAXIES Lung-201,
ITOS: -16% | iteos therapeutics股價下跌。該公司公佈了GALAXIES Lung-201研究的後續中期數據。